Professional background

Dr Jonathan Lambert undertook his specialist training in haematology in London, based at University College Hospital, and completed a PhD in molecular haematology at the UCL Cancer Institute. He currently works as a consultant haemato-oncologist at UCH and Mount Vernon Cancer Centre and has particular expertise in managing lymphoma and myeloproliferative neoplasms, especially more complex cases.

Dr Lambert sits on a number of national committees, including MPN subgroup of the NCRI haematological oncology clinical studies group. He is involved in running a wide variety of clinical studies at UCH and Mount Vernon Cancer Centre, and is responsible for the clinical haematology undergraduate teaching programme at UCH.

Research interests

Clinical trials in myeloproliferative neoplasms and lymphoma


Substituting Carmustine for Lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma - a retrospective study from the BSBMT (BEAM versus LEAM)." Philippa Kelsey, Rachel Pearce, Julia Perry, Keiren Kirkland, Ruth Paul, Jonathan Lambert, Andrew Peniket, Ram Malladi, John Snowden, and Nick Morley. Bone Marrow Transplant 2020 (2020).

Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations. Hebah Ali Ignazio Puccio Ayse U. Akarca Roshanak Bob Sabine Pomplun Wai Keong Wong Rajeev Gupta Mallika Sekhar Jonathan Lambert Hytham Al?Masri Harald Stein Teresa Marafioti. International Journal of Experimental Pathology. September 2020.

Clinical outcomes and risk factors for severe COVID?19 in patients with haematological disorders receiving chemo? or immunotherapy. Thomas A. Fox Ethan Troy?Barnes Amy A. Kirkwood Wei Yee Chan James W. Day Selina J. Chavda Emil A. Kumar Kate David Oliver Tomkins Emilie Sanchez Marie Scully Asim Khwaja Jonathan Lambert Mervyn Singer Claire Roddie Emma C. Morris Kwee L. Yong Kirsty J. Thomson Kirit M. Ardeshna. Br J Haematol. July 2020.

Efficacy of R?BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. McCulloch, R., Visco, C., Eyre, T.A., Frewin, R., Phillips, N., Tucker, D.L., Quaglia, F.M., McMillan, A., Lambert, J., Crosbie, N. and Rule, S. Br J Haematol. 2020. Feb. doi:10.1111/bjh.16416.

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann M, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu S, O'Hare T, Prchal JT, Deininger MW. Blood. 2019 Oct 11.

Challenges in glucoCEST MR body imaging at 3 Tesla. Mina Kim, Francisco Torrealdea, Sola Adeleke, Marilena Rega, Vincent Evans, Teresita Beeston, Katerina Soteriou, Stefanie Thust, Aaron Kujawa, Sachi Okuchi, Elizabeth Isaac, Wivijin Piga, Jonathan Lambert, Asim Afaq, Eleni Demetriou, Pratik Choudhary, King Kenneth Cheung, Sarita Naik, David Atkinson, Shonit Punwani, Xavier Golay. Quantitative Imaging in Medicine and Surgery. October 2019.

Systemic mastocytosis: variable manifestations can lead to a challenging diagnostic process. Susanna Nallamilli, Aideen O’Neill, Andrew Wilson, Mallika Sekhar and Jonathan Lambert. BMJ Case Reports. 2019;12:e229967

HIV-1 remission following CCR5?32/?32 haematopoietic stem-cell transplantation.. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing, Lee H, Grant P, Nastouli E, Lambert J, Pace M, Salasc F, Monit C, Innes AJ, Muir L, Waters L, Frater J, Lever AML, Edwards SG, Gabriel IH, Olavarria E.
Nature. 568: 244–248. March 2019.

Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab. Chen LY, Shah R, Cwynarski K, Lambert J, McNamara C, Mohamedbhai SG, Virchis A, Townsend W, D'Sa S, Ardeshna KM. Br J Haematol. 2018 Jan 24.

Relapsed Hodgkin's lymphoma in pregnancy: A case review. George-Carey R, Parisaei M, Koniman W, Pluckinski M, Lambert J. Obstet Med. 2017 Dec;10(4):183-185

Non-Hodgkin Lymphoma (review). S Ninkovic and J Lambert. Medicine. Volume 45 (5): 297–304. May 2017.

Guideline for the investigation and management of eosinophilia. Nauman M. Butt, Jonathan Lambert, Sahra Ali, Philip A. Beer, Nicholas C. P. Cross, Andrew Duncombe, Joanne Ewing, Claire N. Harrison, Steven Knapper, Donal McLornan, Adam J. Mead, Deepti Radia, and Barbara J. Bain. British Journal of Haematology: 176 (4). February 2017

Comparison of PET/MRI with PET/CT in the Evaluation of Disease Status in Lymphoma. Afaq A, Fraioli F, Sidhu H, Wan S, Punwani S, Chen SH, Akin O, Linch D, Ardeshna K, Lambert J, Miles K, Groves A, Kayani I. Clin Nucl Med. Sept 2016

A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Kothari J, Foley M, Peggs K, Mackenzie S, Thomson K, Morris E, Ardeshna K, Virchis A, Linch D, Lambert J. Bone Marrow Transplant, May 2016.

Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
Maciocia P, Badat M, Cheesman S, D'Sa S, Joshi R, Lambert J, Mohamedbhai S, Pule M, Linch D, & Ardeshna. British Journal of Haematology, 172(4), 545–553, February 2016

Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. Pamela Mckay, Patrick Fielding, Eve Gallop-Evans, Georgina W. Hall, Jonathan Lambert, Mike Leach, Teresa Marafioti, Christopher McNamara. British Journal of Haematology: 172 (1). January 2016.

Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma. Gohil S, Ardeshna K, Lambert J, Pule M, Mohamedbhai S, Virchis A, Morris E, Linch D, Thomson T, and Peggs K. British Journal of Haematology: 171(2), 197–204, October 2015

X-chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations. Allen C, Lambert J, Linch D, and Gale R.
Blood: 124 (13). September 2014.

Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. Kothari J, Peggs KS, Bird A, Thomson KJ, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM. Br J Haematol.(2014) May;165(3):334-40.

Prognostic role of PET scanning before and after reduced intensity allogeneic stem cell transplant for lymphoma. Lambert J, Bomanji J, Peggs K, Thomson K, Chakraverty R, Fielding A, Kottaridis P, Roughton M, Morris E, Goldstone A, Linch D, Ell P & Mackinnon S. Blood (2010). 115(14) 2763-2768.

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Lambert J, Everington T, Linch D & Gale R. Blood (2009). 114(14) 3018-3023.

The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia. Lambert J, Gale R & Linch D. British Journal of Haematolology (2009). 145(1) 128-130.

The JAK2 V617F mutation and thrombosis (review). Austin S & Lambert J.
British Journal of Haematology (2008). 143(3) 307-320.

Audit of the peri-delivery use of unfractionated heparin in women on therapeutic low-molecular heparin. Lambert J, Austin S, Peebles D & Cohen H. British Journal of Haematology (2008). 142(3) 453-458.